{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05081609",
            "orgStudyIdInfo": {
                "id": "ASND0029"
            },
            "organization": {
                "fullName": "Ascendis Pharma A/S",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Investigate Safety and Tolerability of TransCon IL-2 \u03b2/\u03b3 Alone or in Combination With Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies",
            "officialTitle": "IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 \u03b2/\u03b3 Alone or in Combination With Pembrolizumab, Standard of Care Chemotherapy, or TransCon TLR7/8 Agonist, or in Combination With Pembrolizumab and Standard of Care Chemotherapy, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies",
            "acronym": "IL Believe",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-to-investigate-safety-and-tolerability-of-transcon-il-alone-or-in-combination-with-pembrolizumab-and-or-chemotherapy-or-transcon-agonist-in-adult-participants-with-locally-advanced-or-metastatic-solid-tumor-malignancies"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-01-11",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-10-05",
            "studyFirstSubmitQcDate": "2021-10-05",
            "studyFirstPostDateStruct": {
                "date": "2021-10-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Ascendis Pharma Oncology Division A/S",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "TransCon IL-2 \u03b2/\u03b3 is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2 \u03b2/\u03b3 as monotherapy or in combination therapy in adult participants with advanced or metastatic solid tumors. Given the unique PK profile enabled by the TransCon technology, TransCon IL-2 \u03b2/\u03b3 presents the opportunity to enhance the therapeutic index of current IL-2 therapy.",
            "detailedDescription": "IL-2 is a key cytokine that directs the immune system through pleiotropic effects mediated by promoting expansion of both cytotoxic effector cells and Tregs. TransCon IL-2 \u03b2/\u03b3 is designed as a long-acting delivery prodrug of IL-2 \u03b2/\u03b3, a potent cytokine signaling molecule, with the potential to improve the safety and efficacy of IL-2."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor",
                "Locally Advanced Solid Tumor",
                "Metastatic Solid Tumor",
                "Platinum-resistant Ovarian Cancer",
                "Post Anti-PD-1 Melanoma",
                "2L+ Cervical Cancer",
                "Neoadjuvant Melanoma",
                "Neoadjuvant Non-Small Cell Lung Cancer",
                "Post Anti-PD-(L)1 Non-Small Cell Lung Cancer",
                "Post Anti-PD-(L)1 Small Cell Lung Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 393,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1 Monotherapy Dose Escalation: TransCon IL-2 \u03b2/\u03b3",
                    "type": "EXPERIMENTAL",
                    "description": "TransCon IL-2 \u03b2/\u03b3 in escalating doses to evaluate safety/tolerability and to determine the MTD and RP2D",
                    "interventionNames": [
                        "Drug: TransCon IL-2 \u03b2/\u03b3"
                    ]
                },
                {
                    "label": "Part 2 Combination Dose Escalation: TransCon IL-2 \u03b2/\u03b3 with Pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "description": "TransCon IL-2 \u03b2/\u03b3 with Pembrolizumab in escalating doses to evaluate safety/tolerability and determine the MTD and RP2D",
                    "interventionNames": [
                        "Drug: TransCon IL-2 \u03b2/\u03b3",
                        "Drug: Pembrolizumab"
                    ]
                },
                {
                    "label": "Part 3 Combination Dose Expansion: TransCon IL-2 \u03b2/\u03b3 with SOC Chemo",
                    "type": "EXPERIMENTAL",
                    "description": "TransCon IL-2 \u03b2/\u03b3 using the RP2D with SOC Chemotherapy to evaluate safety/tolerability and anti-tumor activity of the combination",
                    "interventionNames": [
                        "Drug: TransCon IL-2 \u03b2/\u03b3",
                        "Drug: Chemotherapy drug"
                    ]
                },
                {
                    "label": "Part 3 Combination Dose Expansion: TransCon IL-2 \u03b2/\u03b3 with TransCon TLR7/8 Agonist",
                    "type": "EXPERIMENTAL",
                    "description": "TransCon IL-2 \u03b2/\u03b3 with TransCon TLR7/8 Agonist using the RP2D to evaluate safety/tolerability and anti-tumor activity of the combination",
                    "interventionNames": [
                        "Drug: TransCon IL-2 \u03b2/\u03b3",
                        "Drug: TransCon TLR7/8 Agonist"
                    ]
                },
                {
                    "label": "Part 3 Monotherapy Dose Expansion: TransCon IL-2 \u03b2/\u03b3 followed by surgery",
                    "type": "EXPERIMENTAL",
                    "description": "(Optional Arm): TransCon IL-2 \u03b2/\u03b3 using the RP2D followed by surgery to evaluate safety/tolerability and anti-tumor activity of the combination",
                    "interventionNames": [
                        "Drug: TransCon IL-2 \u03b2/\u03b3",
                        "Procedure: Surgery"
                    ]
                },
                {
                    "label": "Part 3 Combination Dose Expansion: TransCon IL-2 \u03b2/\u03b3 with Pembrolizumab followed by surgery",
                    "type": "EXPERIMENTAL",
                    "description": "TransCon IL-2 \u03b2/\u03b3 using the RP2D with Pembrolizumab followed by surgery to evaluate safety/tolerability and anti-tumor activity of the combination",
                    "interventionNames": [
                        "Drug: TransCon IL-2 \u03b2/\u03b3",
                        "Drug: Pembrolizumab",
                        "Procedure: Surgery"
                    ]
                },
                {
                    "label": "Part 3 Combination Dose Expansion:TransCon IL-2 \u03b2/\u03b3 with TransCon TLR7/8 Agonist followed by surgery",
                    "type": "EXPERIMENTAL",
                    "description": "TransCon IL-2 \u03b2/\u03b3 with TransCon TLR7/8 Agonist using the RP2D followed by surgery to evaluate safety/tolerability and anti-tumor activity of the combination",
                    "interventionNames": [
                        "Drug: TransCon IL-2 \u03b2/\u03b3",
                        "Drug: TransCon TLR7/8 Agonist",
                        "Procedure: Surgery"
                    ]
                },
                {
                    "label": "Part 3 Combination Dose Expansion:TransCon IL-2 \u03b2/\u03b3 + Pembrolizumab + SOC Chemo followed by surgery",
                    "type": "EXPERIMENTAL",
                    "description": "TransCon IL-2 \u03b2/\u03b3 using the RP2D with Pembrolizumab and SOC Chemotherapy followed by surgery to evaluate safety/tolerability and anti-tumor activity of the combination",
                    "interventionNames": [
                        "Drug: TransCon IL-2 \u03b2/\u03b3",
                        "Drug: Pembrolizumab",
                        "Drug: Chemotherapy drug",
                        "Procedure: Surgery"
                    ]
                },
                {
                    "label": "Part 3 Combination Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "TransCon IL-2 \u03b2/\u03b3 + Pembrolizumab TransCon IL-2 \u03b2/\u03b3 using the RP2D with Pembrolizumab",
                    "interventionNames": [
                        "Drug: TransCon IL-2 \u03b2/\u03b3",
                        "Drug: Pembrolizumab"
                    ]
                },
                {
                    "label": "Part 4 Combination Dose Optimization",
                    "type": "EXPERIMENTAL",
                    "description": "TransCon IL-2 \u03b2/\u03b3 + Pembrolizumab TransCon IL-2 \u03b2/\u03b3 using the RP2D in titrating doses and/or different dose frequencies with Pembrolizumab",
                    "interventionNames": [
                        "Drug: TransCon IL-2 \u03b2/\u03b3",
                        "Drug: Pembrolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "TransCon IL-2 \u03b2/\u03b3",
                    "description": "TransCon IL-2 \u03b2/\u03b3 will be administered as an intravenous (IV) infusion",
                    "armGroupLabels": [
                        "Part 1 Monotherapy Dose Escalation: TransCon IL-2 \u03b2/\u03b3",
                        "Part 2 Combination Dose Escalation: TransCon IL-2 \u03b2/\u03b3 with Pembrolizumab",
                        "Part 3 Combination Dose Expansion",
                        "Part 3 Combination Dose Expansion: TransCon IL-2 \u03b2/\u03b3 with Pembrolizumab followed by surgery",
                        "Part 3 Combination Dose Expansion: TransCon IL-2 \u03b2/\u03b3 with SOC Chemo",
                        "Part 3 Combination Dose Expansion: TransCon IL-2 \u03b2/\u03b3 with TransCon TLR7/8 Agonist",
                        "Part 3 Combination Dose Expansion:TransCon IL-2 \u03b2/\u03b3 + Pembrolizumab + SOC Chemo followed by surgery",
                        "Part 3 Combination Dose Expansion:TransCon IL-2 \u03b2/\u03b3 with TransCon TLR7/8 Agonist followed by surgery",
                        "Part 3 Monotherapy Dose Expansion: TransCon IL-2 \u03b2/\u03b3 followed by surgery",
                        "Part 4 Combination Dose Optimization"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pembrolizumab",
                    "description": "Pembrolizumab will be administered as an intravenous (IV) infusion",
                    "armGroupLabels": [
                        "Part 2 Combination Dose Escalation: TransCon IL-2 \u03b2/\u03b3 with Pembrolizumab",
                        "Part 3 Combination Dose Expansion",
                        "Part 3 Combination Dose Expansion: TransCon IL-2 \u03b2/\u03b3 with Pembrolizumab followed by surgery",
                        "Part 3 Combination Dose Expansion:TransCon IL-2 \u03b2/\u03b3 + Pembrolizumab + SOC Chemo followed by surgery",
                        "Part 4 Combination Dose Optimization"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Chemotherapy drug",
                    "description": "SOC chemotherapy will be administered as an intravenous (IV) infusion",
                    "armGroupLabels": [
                        "Part 3 Combination Dose Expansion: TransCon IL-2 \u03b2/\u03b3 with SOC Chemo",
                        "Part 3 Combination Dose Expansion:TransCon IL-2 \u03b2/\u03b3 + Pembrolizumab + SOC Chemo followed by surgery"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "TransCon TLR7/8 Agonist",
                    "description": "TransCon TLR7/8 Agonist will be administered as an IT (Intratumoral) injection",
                    "armGroupLabels": [
                        "Part 3 Combination Dose Expansion: TransCon IL-2 \u03b2/\u03b3 with TransCon TLR7/8 Agonist",
                        "Part 3 Combination Dose Expansion:TransCon IL-2 \u03b2/\u03b3 with TransCon TLR7/8 Agonist followed by surgery"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Surgery",
                    "description": "Surgery will take place 4-6 weeks after last dose of study treatment.",
                    "armGroupLabels": [
                        "Part 3 Combination Dose Expansion: TransCon IL-2 \u03b2/\u03b3 with Pembrolizumab followed by surgery",
                        "Part 3 Combination Dose Expansion:TransCon IL-2 \u03b2/\u03b3 + Pembrolizumab + SOC Chemo followed by surgery",
                        "Part 3 Combination Dose Expansion:TransCon IL-2 \u03b2/\u03b3 with TransCon TLR7/8 Agonist followed by surgery",
                        "Part 3 Monotherapy Dose Expansion: TransCon IL-2 \u03b2/\u03b3 followed by surgery"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety and Tolerability",
                    "description": "Treatment emergent and treatment related adverse events (assessed by NCI CTCAE v5.0), serious adverse events (SAEs), adverse events leading to treatment discontinuation, deaths.",
                    "timeFrame": "Through study completion, expected average of 2 years"
                },
                {
                    "measure": "Maximum Tolerated Dose (MTD)",
                    "description": "Determine the maximum tolerated dose by assessing the Incidence of Dose Limiting Toxicities (DLTs), treatment emergent and treatment related adverse events (assessed by NCI CTCAE v5.0), serious adverse events (SAEs), adverse events leading to treatment discontinuation and deaths.",
                    "timeFrame": "Each cycle is 21 days"
                },
                {
                    "measure": "Recommended Phase 2 Dose (RP2D)",
                    "description": "To determine a recommended phase 2 dose of TransCon IL-2 \u03b2/\u03b3 and combination regimen for further development by evaluating number of patients with treatment-related adverse events as assessed by CTCAE.",
                    "timeFrame": "12 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall Response Rate",
                    "description": "Response assessed by RECIST v1.1",
                    "timeFrame": "Average of 2 years"
                },
                {
                    "measure": "Pathologic Complete Response",
                    "description": "Evaluate the pathologic Complete Response (pCR) for anti-tumor activity of TransCon IL-2 \u03b2/\u03b3 alone or in combination with pembrolizumab, or TransCon TLR7/8 Agonist, or in combination with pembrolizumab and SOC chemotherapy in the Neoadjuvant Cohorts",
                    "timeFrame": "15 weeks"
                },
                {
                    "measure": "Major Pathologic Response",
                    "description": "Evaluate the Major Pathologic Response (MPR) for anti-tumor activity of TransCon IL-2 \u03b2/\u03b3 alone or in combination with pembrolizumab, or TransCon TLR7/8 Agonist, or in combination with pembrolizumab and SOC chemotherapy in the Neoadjuvant Cohorts",
                    "timeFrame": "15 weeks"
                },
                {
                    "measure": "Duration of Response",
                    "description": "Time from first documentation of objective tumor response (CR or PR that is subsequently confirmed) to first documentation of disease progression or death due to any cause, whichever occurs first",
                    "timeFrame": "Average of 2 years"
                },
                {
                    "measure": "Time to Response",
                    "description": "Time from date of first dose of study treatment to first occurrence of response (CR or PR)",
                    "timeFrame": "Expected up to 1 year from first dose"
                },
                {
                    "measure": "Progression Free Survival (PFS)",
                    "description": "Time from date of first dose of study treatment to first documentation of disease progression or death due to any cause",
                    "timeFrame": "Average of 2 years"
                },
                {
                    "measure": "Event free survival (EFS) by RECIST 1.1",
                    "description": "Time from the date of the first dose of study treatment to the occurrence of any of the following: progression of disease that precludes surgery, disease recurrence after surgery, or death from any cause.",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Overall Survival (OS)",
                    "description": "Time from date of first dose of study treatment to date of death due to any cause",
                    "timeFrame": "Average of 2 years"
                },
                {
                    "measure": "PK Characterization (Cmax)",
                    "description": "Maximum observed plasma concentration of TransCon IL-2 \u03b2/\u03b3 and Free IL-2 \u03b2/\u03b3 after IV administration of TransCon IL-2 \u03b2/\u03b3 alone or in combination with other therapies",
                    "timeFrame": "Average of 2 years"
                },
                {
                    "measure": "PK Characterization (Tmax)",
                    "description": "Time to reach maximum plasma concentration of TransCon IL-2 \u03b2/\u03b3 and Free IL-2 \u03b2/\u03b3 after IV administration of TransCon IL-2 \u03b2/\u03b3 alone or in combination other therapies",
                    "timeFrame": "Average of 2 years"
                },
                {
                    "measure": "PK Characterization (AUClast)",
                    "description": "Area under the plasma concentration curve from time zero to last sampling time at which the concentration is at or above the lower limit of quantification for TransCon IL-2 \u03b2/\u03b3 and Free IL-2 \u03b2/\u03b3 after IV administration of TransCon IL-2 \u03b2/\u03b3 alone or in combination with other therapies",
                    "timeFrame": "Average of 2 years"
                },
                {
                    "measure": "PK Characterization (AUC0-t)",
                    "description": "Area under the plasma concentration curve from time zero to time t for TransCon IL-2 \u03b2/\u03b3 and Free IL-2 \u03b2/\u03b3 after IV administration of TransCon IL-2 \u03b2/\u03b3 alone or in combination with other therapies",
                    "timeFrame": "Average of 2 years"
                },
                {
                    "measure": "PK Characterization (t1/2)",
                    "description": "Apparent terminal half-life of TransCon IL-2 \u03b2/\u03b3 and Free IL-2 \u03b2/\u03b3 after IV administration of TransCon IL-2 \u03b2/\u03b3 alone or in combination with other therapies",
                    "timeFrame": "Average of 2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* At least 18 years of age\n* Demonstrated adequate organ function at screening\n* Life expectancy \\>12 weeks as determined by the Investigator\n* Female and male participants of childbearing potential who are sexually active must agree to use highly effective methods of contraception\n* Participants must have histologically confirmed locally advanced, recurrent, or metastatic solid tumor malignancies that cannot be treated with curative intent (surgery or radiotherapy), with the exception of the neoadjuvant cohorts\n* Part 1 and Part 2: Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2\n* Part 3 and Part 4: Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Participants who have undergone treatment with anti-PD-1, anti-PD-L1, or anti-cytotoxic T-lymphocyte-associated protein (CTLA-4) antibody must have a washout of at least 4 weeks from the last dose and evidence of disease progression per investigator assessment before Cycle 1 Day 1 (C1D1) with the exception of the neoadjuvant cohorts\n* Participants who have previously received an immunotherapy prior to C1D1 must have any immune-related toxicities resolved to \u2264Grade 1 or baseline (prior to the immunotherapy) to be eligible, with the exception of participants on well controlled physiologic endocrine replacement\n* Part 3: Neoadjuvant cohorts: participants must have completely resectable disease\n\nKey Exclusion Criteria:\n\n* Symptomatic central nervous system metastases and/or carcinomatous meningitis\n* Active autoimmune diseases, regardless of need for immunosuppressive treatment, with the exception of participants well controlled on physiologic endocrine replacement\n* Any uncontrolled bacterial, fungal, viral, or other infection\n* Significant cardiac disease\n* A marked clinically significant baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \\>480 ms) \\[CTCAE Grade 1\\]) using Fridericia's QT correction formula\n* Positive for human immunodeficiency virus (HIV) or has known active hepatitis B or C infection\n* Known hypersensitivity to any study treatment(s) used in the specific study part/cohort\n* Part 3, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, and Neoadjuvant Melanoma: Participants who have been previously treated with IL-2 or IL-2 variants (all participants), or TLR agonist\n* Systemic immunosuppressive treatment with the exception for patients on corticosteroid taper (for example, for chronic obstructive pulmonary disease exacerbation).\n* Vaccination with live, attenuated vaccines within 4 weeks of C1D1\n* Treatment with any other anti-cancer systemic treatment (approved or investigational) or radiation therapy within 4 weeks of C1D1\n* Part 3: Other active malignancies within the last 2 years\n* Women who are breastfeeding or have a positive serum pregnancy test during screening",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Ascendis Oncology Clinical Trials",
                    "role": "CONTACT",
                    "phone": "+1 650-352-8389",
                    "email": "OncologyClinicalTrials@ascendispharma.com"
                },
                {
                    "name": "Davis Ascendis Oncology Clinical Trials",
                    "role": "CONTACT",
                    "phone": "+1 650-352-8389",
                    "email": "OncologyClinicalTrials@ascendispharma.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Davis Torrejon-Castro",
                    "affiliation": "Medical Monitor",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90048",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90067",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "TERMINATED",
                    "city": "Huntersville",
                    "state": "North Carolina",
                    "zip": "28078",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.41069,
                        "lon": -80.84285
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Canton",
                    "state": "Ohio",
                    "zip": "44718",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.79895,
                        "lon": -81.37845
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45219",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Oklahoma City",
                    "state": "Oklahoma",
                    "zip": "73104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.46756,
                        "lon": -97.51643
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15232",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Richmond",
                    "state": "Virginia",
                    "zip": "23298",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.55376,
                        "lon": -77.46026
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Adelaide",
                    "zip": "5000",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -34.92866,
                        "lon": 138.59863
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Adelaide",
                    "zip": "5042",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -34.92866,
                        "lon": 138.59863
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Frankston",
                    "zip": "3199",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -38.14458,
                        "lon": 145.12291
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Southport",
                    "zip": "4215",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -27.96724,
                        "lon": 153.39796
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "TERMINATED",
                    "city": "Toorak Gardens",
                    "zip": "05065",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -34.93478,
                        "lon": 138.63639
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Waratah",
                    "zip": "2298",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -32.90667,
                        "lon": 151.72647
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Wilrijk",
                    "zip": "2610",
                    "country": "Belgium",
                    "geoPoint": {
                        "lat": 51.16734,
                        "lon": 4.39513
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Montr\u00e9al",
                    "zip": "H4A 3J1",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "zip": "M4N 3M5",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Lido Di Camaiore",
                    "zip": "55041",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 43.90012,
                        "lon": 10.2269
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Livorno",
                    "zip": "57124",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 43.54427,
                        "lon": 10.32615
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Meldola",
                    "zip": "47014",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 44.12775,
                        "lon": 12.0626
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Turin",
                    "zip": "10060",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.07049,
                        "lon": 7.68682
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Songpa-gu",
                    "zip": "05505",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Seongnam-si",
                    "zip": "13620",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.43861,
                        "lon": 127.13778
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "03080",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "03722",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "06231",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "06351",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Krak\u00f3w",
                    "zip": "31-501",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 50.06143,
                        "lon": 19.93658
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Pozna\u0144",
                    "zip": "60693",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 52.40692,
                        "lon": 16.92993
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Warszawa",
                    "zip": "02-781",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 52.22977,
                        "lon": 21.01178
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Singapore",
                    "zip": "217562",
                    "country": "Singapore",
                    "geoPoint": {
                        "lat": 1.28967,
                        "lon": 103.85007
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08023",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28027",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28050",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Murcia",
                    "zip": "30120",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 37.98704,
                        "lon": -1.13004
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "M\u00e1laga",
                    "zip": "29010",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 36.72016,
                        "lon": -4.42034
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Pamplona",
                    "zip": "31008",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 42.81687,
                        "lon": -1.64323
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Sevilla",
                    "zip": "41009",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 37.38283,
                        "lon": -5.97317
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Valencia",
                    "zip": "46009",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 39.46975,
                        "lon": -0.37739
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Taipei",
                    "zip": "10002",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 25.04776,
                        "lon": 121.53185
                    }
                },
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Taipei",
                    "zip": "11259",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 25.04776,
                        "lon": 121.53185
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "35817480",
                    "type": "DERIVED",
                    "citation": "Rosen DB, Kvarnhammar AM, Laufer B, Knappe T, Karlsson JJ, Hong E, Lee YC, Thakar D, Zuniga LA, Bang K, Sabharwal SS, Uppal K, Olling JD, Kjaergaard K, Kurpiers T, Schnabel M, Reich D, Glock P, Zettler J, Krusch M, Bernhard A, Heinig S, Konjik V, Wegge T, Hehn Y, Killian S, Viet L, Runz J, Faltinger F, Tabrizi M, Abel KL, Breinholt VM, Singel SM, Sprogoe K, Punnonen J. TransCon IL-2 beta/gamma: a novel long-acting prodrug with sustained release of an IL-2Rbeta/gamma-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer. J Immunother Cancer. 2022 Jul;10(7):e004991. doi: 10.1136/jitc-2022-004991."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                },
                {
                    "id": "D000008545",
                    "term": "Melanoma"
                },
                {
                    "id": "D000055752",
                    "term": "Small Cell Lung Carcinoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                },
                {
                    "id": "D000018358",
                    "term": "Neuroendocrine Tumors"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                },
                {
                    "id": "D000018326",
                    "term": "Nevi and Melanomas"
                },
                {
                    "id": "D000012878",
                    "term": "Skin Neoplasms"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Non-small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5830",
                    "name": "Uterine Cervical Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "asFound": "Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M28323",
                    "name": "Small Cell Lung Carcinoma",
                    "asFound": "Small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11528",
                    "name": "Melanoma",
                    "asFound": "Melanoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M20495",
                    "name": "Neuroendocrine Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M12448",
                    "name": "Nevus, Pigmented",
                    "relevance": "LOW"
                },
                {
                    "id": "M12446",
                    "name": "Nevus",
                    "relevance": "LOW"
                },
                {
                    "id": "M20470",
                    "name": "Nevi and Melanomas",
                    "relevance": "LOW"
                },
                {
                    "id": "M15681",
                    "name": "Skin Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T5271",
                    "name": "Small Cell Lung Cancer",
                    "asFound": "Small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T4091",
                    "name": "Neuroendocrine Tumor",
                    "relevance": "LOW"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}